PLAG alleviates cisplatin-induced cachexia in lung cancer implanted mice

Kim, Guen Tae; Kim, Eun Young; Shin, Su‐Hyun; Lee, Hyowon; Lee, Se Hee; Park, Kaapjoo; Sohn, Ki-Young; Yoon, Sun Young; Kim, Jae Wha

doi:10.1016/j.tranon.2022.101398

Cited by 4 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, few studies of treatment or prevention of systemic cancer therapy-induced myopathy are available and for now most evidence is from animal models. Therapeutics with evidence for efficacy include eicosapentaenoic acid [42], 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) [48], a soy-derived isoflavone (daidzein) [37], exercise [45], a proteasome inhibitor (bortezomib) [41], and Chinese herbal medicine formula Yifei sanjie [46]. As all these results have been obtained in single studies and the animal models in which they were conducted are of unknown translational relevance, further investigation is needed.…”

Section: Therapeutic Strategies To Mitigate Systemic Cancer Therapy-i...mentioning

confidence: 99%

See 1 more Smart Citation

Adverse effects of systemic cancer therapy on skeletal muscle: myotoxicity comes out of the closet

Klassen

Schiessel

Baracos

2023

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

Purpose of reviewSystemic cancer therapy-associated skeletal muscle wasting is emerging as a powerful impetus to the overall loss of skeletal muscle experienced by patients with cancer. This review explores the clinical magnitude and biological mechanisms of muscle wasting during systemic cancer therapy to illuminate this adverse effect. Emerging strategies for mitigation are also discussed.Recent findingsClinical findings include precise, specific measures of muscle loss over the course of chemotherapy, targeted therapy and immunotherapy. All these therapeutic classes associate with quantitatively important muscle loss, independent of tumor response. Parallel experimental studies provide understanding of the specific molecular basis of wasting, which can include inhibition of protein synthesis, proliferation and differentiation, and activation of inflammation, reactive oxygen species, autophagy, mitophagy, apoptosis, protein catabolism, fibrosis and steatosis in muscle. Strategies to mitigate these muscle-specific adverse effects of cancer therapy remain in the earliest stages of development.SummaryThe adverse side effect of cancer therapy on skeletal muscle has been largely ignored in the development of cancer therapeutics. Given the extent to which loss of muscle mass and function can bear on patients’ function and quality of life, protection/mitigation of these side effects is a research priority.

show abstract

Section: Therapeutic Strategies To Mitigate Systemic Cancer Therapy-i...mentioning

confidence: 99%

“…Cisplatin remains the most intensively studied individual compound [35][36][37][40][41][42][43][44][46][47][48]. Cisplatin suppresses protein synthesis via an Akt protein kinase B (Akt)-dependent mechanism, which leads to p70S6k1 dephosphorylation.…”

Section: Molecular Pathways Of Systemic Treatment-related Muscle Lossmentioning

confidence: 99%